Post-COVID lung fibrosis: The tsunami that will follow the earthquake

Zarir F Udwadia, Parvaiz A Koul, Luca Richeldi, Zarir F Udwadia, Parvaiz A Koul, Luca Richeldi

Abstract

The SARS-CoV-2 pandemic has already infected in excess of 50 million people worldwide and resulted in 1.2 million deaths. While the majority of those infected will not have long-term pulmonary sequelae, 5%-10% will develop severe COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). The natural history of these severely affected patients is unclear at present, but using our knowledge of closely related coronavirus outbreaks like severe acute respiratory distress syndrome (SARS) and middle east respiratory syndrome (MERS), we would hypothesize that the majority will stabilize or improve over time although some patients will progress to advanced lung fibrosis or post-COVID interstitial lung disease (PC-ILD). Unlike the SARS and MERS outbreaks which affected only a few thousands, the sheer scale of the present pandemic suggests that physicians are likely to encounter large numbers of patients (potentially hundreds of thousands) with PC-ILD. In this review, we discuss the pathogenesis, natural history, and radiology of such patients and touch on clinical, laboratory, and radiographic clues at presentation which might help predict the future development of lung fibrosis. Finally, we discuss the responsible use of antifibrotic drugs such as pirfenidone, nintedanib, and some newer antifibrotics, still in the pipeline. The biological rationale of these drugs and the patient groups where they may have a plausible role will be discussed. We conclude by stressing the importance of careful longitudinal follow-up of multiple cohorts of post-COVID survivors with serial lung function and imaging. This will eventually help to determine the natural history, course, and response to therapy of these patients.

Keywords: Antifibrotics; fibrosis; post COVID ILD; post-COVID fibrosis; post-COVID sequelae.

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Postulated mechanism of SARS-CoV-2 induced fibrosis stressing the pivotal role of Angiotensin 2
Figure 2
Figure 2
Rapid progression of COVID-19 to end-stage post-COVID interstitial lung disease in

Figure 3

The natural history of post-COVID…

Figure 3

The natural history of post-COVID lung fibrosis is unclear with one of three…

Figure 3
The natural history of post-COVID lung fibrosis is unclear with one of three possible courses. Antifibrotic may have a rationale in those who progress

Figure 4

(a) Initial computed tomography chest…

Figure 4

(a) Initial computed tomography chest of a 60-year-old lady admitted in the intensive…

Figure 4
(a) Initial computed tomography chest of a 60-year-old lady admitted in the intensive care unit showing bilateral ground-glass opacities. (b) Within 3 month of COVID-19 pneumonia, the patient developed fibrosis with traction bronchiectasis and honeycombing despite being on steroids through most of her hospital stay
Figure 3
Figure 3
The natural history of post-COVID lung fibrosis is unclear with one of three possible courses. Antifibrotic may have a rationale in those who progress
Figure 4
Figure 4
(a) Initial computed tomography chest of a 60-year-old lady admitted in the intensive care unit showing bilateral ground-glass opacities. (b) Within 3 month of COVID-19 pneumonia, the patient developed fibrosis with traction bronchiectasis and honeycombing despite being on steroids through most of her hospital stay

References

    1. Wen Y, Deng BC, Zhou Y, Wang Y, Cui W, Wang W, et al. Immunological features in patients with pneumonitis due to influenza A H1N1 infection. J Investig Allergol Clin Immunol. 2011;21:44–50.
    1. Jolly L, Stavrou A, Vanderstoken G, Meliopoulos VA, Habgood A, Tatler AL, et al. Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation. Biol Chem. 2014;289:35246–63.
    1. Baas T, Taubenberger JK, Chong PY, Chui P, Katze MG. SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues. J Interf Cytokine Res. 2006;26:309–17.
    1. Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res. 2020;21:182.
    1. Delpino MV, Quarleri J. SARS-CoV-2 Pathogenesis: Imbalance in the renin-angiotensin system favors lung fibrosis. Front Cell Infect Microbiol. 2020;10:340.
    1. Mach WJ, Thimmesch AR, Pierce JT, Pierce JD. Consequences of hyperoxia and the toxicity of oxygen in the lung. Nurs Res Pract. 2011;2011:1–7.
    1. Albert RK, Smith B, Perlman CE, Schwartz DA. Is progression of pulmonary fibrosis due to ventilation-induced lung injury? Am J Resp Critical Care Med Am Thoracic Soc. 2019;200:140–51.
    1. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Resp Med. 2020;8:807–15.
    1. Singh N, Singh S, Sharma B, Singh V. Swine flu fibrosis: Regressive or progressive? Lung India. 2016;33:219.
    1. Wang Q, Jiang H, Xie Y, Zhang T, Liu S, Wu S, et al. Long-term clinical prognosis of human infections with avian influenza A (H7N9) viruses in China after hospitalization. EClinicalMedicine. 2020;20:100282.
    1. Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM, Hsiao CH, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: Evaluation with thin-section CT. Radiology. 2005;236:1067–75.
    1. Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8.
    1. Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
    1. Arnold DT, Hamilton FW, Milne A, Morley A, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. medRxiv. 2020 .
    1. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Vol.55, European Respiratory Journal. European Respiratory Society. 2020
    1. Lv D, Chen X, Wang X, Mao L, Sun J, Wu G, et al. Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study. Ann Palliat Med. 2020;9:3447–52.
    1. Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21:746–55.
    1. Persistent Lung Damage Improves Gradually After COVID-19. [Last accessed on 2020 Oct 20]. Available from: .
    1. Xiong Y, Sun D, Liu Y, Fan Y, Zhao L, Li X, et al. Clinical and high-resolution CT features of the COVID-19 infection. Invest Radiol. 2020;55:332–9.
    1. Schwensen HF, Borreschmidt LK, Storgaard M, Redsted S, Christensen S, Madsen LB. Fatal pulmonary fibrosis: A post-COVID-19 autopsy case. J Clin Pathol. 2020 Jul;28:1–3.
    1. Wei J, Yang H, Lei P, Fan B, Qiu Y, Zeng B, et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol. 2020;28:383–9.
    1. Li X, Zeng W, Li X, Chen H, Shi L, Li X, et al. CT imaging changes of corona virus disease 2019 (COVID-19): A multi-center study in Southwest China. Transl Med. 2020;18:154.
    1. Ahmed H, Patel K, Greenwood D, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or icu admission: A systematic review and meta-analysis of follow-up studies. medRxiv. 2020. Apr 22, 2020.04.16.20067975. Available from: .
    1. British Thoracic Society. British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia. Br Thorac Soc. 2020. May, Available from:
    1. Schaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M, Märkl B, et al. Postmortem examination of patients with COVID-19. JAMA. 2020;323:2518.
    1. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med. 1998;157:S123–9.
    1. Udwadia ZF, Pokhariyal P, Tripathi AR, Kohli A. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India. 2021;38:S61–3.
    1. Kayhan S, Kocakoç E. Pulmonary fibrosis due to COVID-19 pneumonia. Korean J Radiol. 2020;21:1273.
    1. Hu Q, Guan H, Sun Z, Huang L, Chen C, Ai T, et al. Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China. Eur J Radiol. 2020;128:109017.
    1. Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa G Della, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Resp Med. 2020;8:750–2.
    1. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulm Med. 2020;2020:6175964.
    1. Wallace WA, Fitch PM, Simpson AJ, Howie SE. Inflammation-associated remodelling and fibrosis in the lung A process and an end point. Int J Exp Pathol. 2007;88:103–10.
    1. Das K, Lee E, Singh R, Enani M, Al Dossari K, van Gorkom K, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imag. 2017;27:342.
    1. Wong KT, Antonio GE, Hui DS, Ho C, Chan PN, Ng WH, et al. Severe acute respiratory syndrome: Thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. Comput Assist Tomogr. 2004;28:790–5.
    1. Low-cost Dexamethasone Reduces Death by up to one Third in Hospitalised Patients with Severe Respiratory Complications of COVID-19 – RECOVERY Trial. [Last accessed on 2020 Oct 20]. Available from: .
    1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.
    1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.
    1. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.
    1. Polastri M, Nava S, Clini E, Vitacca M, Gosselink R. COVID-19 and pulmonary rehabilitation: Preparing for phase three. Eur Respir J. 2020:55.
    1. Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int J Infect Dis. 2020;96:683–7.
    1. Lang C, Jaksch P, Hoda MA, Lang G, Staudinger T, Tschernko E, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med. 2020;8:1057–60.
    1. Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir Med. 2020;8:839–42.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する